Korsana Biosciences emerged from stealth with $175 million in seed and Series A financing to develop KRSA‑028, a monoclonal antibody designed to clear amyloid‑beta plaques in Alzheimer’s disease using a blood‑brain‑barrier shuttle approach. Investors include Wellington Management, J.P. Morgan Life Sciences Private Capital and Sanofi Ventures. Korsana plans first‑in‑human studies by early 2027 with initial safety data midyear and proof‑of‑concept plaque reduction results targeted by year‑end. The raise funds early clinical execution and underscores persistent investor appetite for anti‑amyloid strategies despite a crowded field.